Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients.

Zhan H, Cardozo C, Yu W, Wang A, Moliterno AR, Dang CV, Spivak JL.

Blood Cells Mol Dis. 2013 Mar;50(3):190-5. doi: 10.1016/j.bcmd.2012.11.009. Epub 2012 Dec 21.

PMID:
23265742
2.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
3.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

4.

Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis.

Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT.

Exp Hematol. 2007 Nov;35(11):1657-67.

5.

Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.

Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL.

Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23.

6.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
7.

Polycythemia vera: scientific advances and current practice.

Tefferi A, Spivak JL.

Semin Hematol. 2005 Oct;42(4):206-20. Review.

PMID:
16210034
9.

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.

Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupré N, Skoda RC, Hermouet S.

Blood. 2006 Sep 15;108(6):1865-7. Epub 2006 May 25.

10.

Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.

Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R, Bayram M, Gorukmez O, Ocakoglu G.

Mol Biol Rep. 2012 Sep;39(9):8663-7. doi: 10.1007/s11033-012-1721-x. Epub 2012 Jun 22.

PMID:
22722988
11.

JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.

Zhang S, Qiu H, Fischer BS, Li W, Duan L, Sun X, Xu W, Li J.

Leuk Lymphoma. 2008 Apr;49(4):696-9. doi: 10.1080/10428190701885537.

PMID:
18398736
12.

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.

Duek A, Lundberg P, Shimizu T, Grisouard J, Karow A, Kubovcakova L, Hao-Shen H, Dirnhofer S, Skoda RC.

Blood. 2014 Jun 19;123(25):3943-50. doi: 10.1182/blood-2013-07-514208. Epub 2014 May 12.

13.
14.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
15.

Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.

Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD.

Clin Cancer Res. 2010 Sep 1;16(17):4339-52. doi: 10.1158/1078-0432.CCR-10-1092. Epub 2010 Jul 2.

16.

Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.

Ho CL, Wu YY, Hung HM, Chang PY, Kao WY, Chen YC, Chao TY.

J Formos Med Assoc. 2012 Jan;111(1):34-40. doi: 10.1016/j.jfma.2012.01.003. Epub 2012 Feb 1.

17.

Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.

Treliński J, Wierzbowska A, Krawczyńska A, Sakowicz A, Pietrucha T, Smolewski P, Robak T, Chojnowski K.

Int J Hematol. 2010 Jun;91(5):792-8. doi: 10.1007/s12185-010-0596-7. Epub 2010 May 15.

PMID:
20473593
18.
19.

Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.

Martini M, Teofili L, Larocca LM.

Methods Mol Med. 2006;125:265-73.

PMID:
16502591
20.

Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.

Ismael O, Shimada A, Hama A, Sakaguchi H, Doisaki S, Muramatsu H, Yoshida N, Ito M, Takahashi Y, Akita N, Sunami S, Ohtsuka Y, Asada Y, Fujisaki H, Kojima S.

Pediatr Blood Cancer. 2012 Sep;59(3):530-5. doi: 10.1002/pbc.23409. Epub 2011 Nov 21.

PMID:
22106054
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk